GlucoTrack, Inc. (NASDAQ: IGAP) Stock Competitors & Peer Comparison
See IGAP's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for IGAP and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IGAP | $3.24 | +2.86% | 50.2M | -10.52 | -$0.31 | N/A |
| ISRG | $391.95 | -2.32% | 138.5B | 40.74 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.25% |
| BDX | $176.80 | -0.71% | 48.7B | 13.60 | $13.00 | +2.25% |
| RMD | $218.89 | -1.02% | 31.8B | 20.33 | $10.77 | +1.12% |
| MDLN | $35.61 | +1.92% | 30.1B | 26.09 | $1.36 | N/A |
| WST | $364.98 | -0.01% | 25.7B | 42.94 | $8.50 | +0.24% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $87.85 | +0.09% | 15.2B | 12.37 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.25% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
IGAP vs ISRG Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ISRG has a market cap of 138.5B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while ISRG trades at $391.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ISRG's P/E ratio is 40.74. In terms of profitability, IGAP's ROE is +1.80%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, IGAP is less volatile compared to ISRG. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
IGAP vs BDXA Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas BDXA's P/E ratio is 45.70. In terms of profitability, IGAP's ROE is +1.80%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, IGAP is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
IGAP vs BDX Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, BDX has a market cap of 48.7B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while BDX trades at $176.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas BDX's P/E ratio is 13.60. In terms of profitability, IGAP's ROE is +1.80%, compared to BDX's ROE of +0.04%. Regarding short-term risk, IGAP is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check BDX's competition here
ResMed Inc. (NYSE: RMD)
IGAP vs RMD Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, RMD has a market cap of 31.8B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while RMD trades at $218.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas RMD's P/E ratio is 20.33. In terms of profitability, IGAP's ROE is +1.80%, compared to RMD's ROE of +0.24%. Regarding short-term risk, IGAP is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check RMD's competition here
Medline Inc. (NASDAQ: MDLN)
IGAP vs MDLN Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, MDLN has a market cap of 30.1B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while MDLN trades at $35.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas MDLN's P/E ratio is 26.09. In terms of profitability, IGAP's ROE is +1.80%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, IGAP is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
IGAP vs WST Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, WST has a market cap of 25.7B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while WST trades at $364.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas WST's P/E ratio is 42.94. In terms of profitability, IGAP's ROE is +1.80%, compared to WST's ROE of +0.19%. Regarding short-term risk, IGAP is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
IGAP vs HOLX Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas HOLX's P/E ratio is 31.54. In terms of profitability, IGAP's ROE is +1.80%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, IGAP is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
IGAP vs SOLV Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, SOLV has a market cap of 15.2B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while SOLV trades at $87.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas SOLV's P/E ratio is 12.37. In terms of profitability, IGAP's ROE is +1.80%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, IGAP is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
IGAP vs BDXB Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas BDXB's P/E ratio is 7.60. In terms of profitability, IGAP's ROE is +1.80%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, IGAP is less volatile compared to BDXB. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
IGAP vs BAX Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, BAX has a market cap of 12.1B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while BAX trades at $23.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas BAX's P/E ratio is 11.29. In terms of profitability, IGAP's ROE is +1.80%, compared to BAX's ROE of -0.17%. Regarding short-term risk, IGAP is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check BAX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
IGAP vs COO Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, COO has a market cap of 11.1B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while COO trades at $56.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas COO's P/E ratio is 12.48. In terms of profitability, IGAP's ROE is +1.80%, compared to COO's ROE of +0.07%. Regarding short-term risk, IGAP is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check COO's competition here
Avantor, Inc. (NYSE: AVTR)
IGAP vs AVTR Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, AVTR has a market cap of 10.4B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while AVTR trades at $15.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas AVTR's P/E ratio is 18.04. In terms of profitability, IGAP's ROE is +1.80%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, IGAP is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
IGAP vs RGEN Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, RGEN has a market cap of 10.3B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while RGEN trades at $181.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas RGEN's P/E ratio is 100.94. In terms of profitability, IGAP's ROE is +1.80%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, IGAP is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check RGEN's competition here
AptarGroup, Inc. (NYSE: ATR)
IGAP vs ATR Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ATR has a market cap of 7.7B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while ATR trades at $119.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ATR's P/E ratio is 20.97. In terms of profitability, IGAP's ROE is +1.80%, compared to ATR's ROE of +0.14%. Regarding short-term risk, IGAP is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
IGAP vs BLCO Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, BLCO has a market cap of 6.1B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while BLCO trades at $17.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas BLCO's P/E ratio is 26.31. In terms of profitability, IGAP's ROE is +1.80%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, IGAP is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
IGAP vs STVN Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, STVN has a market cap of 5.5B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while STVN trades at $20.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas STVN's P/E ratio is 30.55. In terms of profitability, IGAP's ROE is +1.80%, compared to STVN's ROE of +0.09%. Regarding short-term risk, IGAP is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check STVN's competition here
Teleflex Incorporated (NYSE: TFX)
IGAP vs TFX Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, TFX has a market cap of 5.5B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while TFX trades at $124.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas TFX's P/E ratio is 14.19. In terms of profitability, IGAP's ROE is +1.80%, compared to TFX's ROE of -0.32%. Regarding short-term risk, IGAP is less volatile compared to TFX. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
IGAP vs MMSI Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, MMSI has a market cap of 5.1B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while MMSI trades at $85.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas MMSI's P/E ratio is 21.83. In terms of profitability, IGAP's ROE is +1.80%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, IGAP is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
IGAP vs ICUI Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ICUI has a market cap of 4B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while ICUI trades at $159.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ICUI's P/E ratio is 19.90. In terms of profitability, IGAP's ROE is +1.80%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, IGAP is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
IGAP vs NVST Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NVST has a market cap of 3.8B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while NVST trades at $23.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NVST's P/E ratio is 15.96. In terms of profitability, IGAP's ROE is +1.80%, compared to NVST's ROE of +0.03%. Regarding short-term risk, IGAP is less volatile compared to NVST. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
IGAP vs PLSE Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, PLSE has a market cap of 3.3B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while PLSE trades at $47.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas PLSE's P/E ratio is -40.59. In terms of profitability, IGAP's ROE is +1.80%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, IGAP is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
IGAP vs ATRC Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ATRC has a market cap of 2.8B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while ATRC trades at $55.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ATRC's P/E ratio is 1712.42. In terms of profitability, IGAP's ROE is +1.80%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, IGAP is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
IGAP vs BLFS Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, BLFS has a market cap of 1.8B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while BLFS trades at $37.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas BLFS's P/E ratio is 36.21. In terms of profitability, IGAP's ROE is +1.80%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, IGAP is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check BLFS's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
IGAP vs LMAT Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while LMAT trades at $78.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas LMAT's P/E ratio is 29.03. In terms of profitability, IGAP's ROE is +1.80%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, IGAP is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check LMAT's competition here
Azenta, Inc. (NASDAQ: AZTA)
IGAP vs AZTA Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, AZTA has a market cap of 1.8B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while AZTA trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas AZTA's P/E ratio is 92.26. In terms of profitability, IGAP's ROE is +1.80%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, IGAP is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check AZTA's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
IGAP vs XRAY Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, XRAY has a market cap of 1.7B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while XRAY trades at $8.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas XRAY's P/E ratio is 6.06. In terms of profitability, IGAP's ROE is +1.80%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, IGAP is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check XRAY's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
IGAP vs KMTS Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while KMTS trades at $27.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas KMTS's P/E ratio is -10.35. In terms of profitability, IGAP's ROE is +1.80%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, IGAP is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
IGAP vs STAA Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, STAA has a market cap of 1.1B. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while STAA trades at $22.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas STAA's P/E ratio is 39.42. In terms of profitability, IGAP's ROE is +1.80%, compared to STAA's ROE of +0.01%. Regarding short-term risk, IGAP is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
IGAP vs ATRI Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ATRI's P/E ratio is 64.50. In terms of profitability, IGAP's ROE is +1.80%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, IGAP is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
IGAP vs ANGO Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ANGO has a market cap of 624.5M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while ANGO trades at $15.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ANGO's P/E ratio is -38.74. In terms of profitability, IGAP's ROE is +1.80%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, IGAP is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check ANGO's competition here
Embecta Corp. (NASDAQ: EMBC)
IGAP vs EMBC Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, EMBC has a market cap of 335.2M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while EMBC trades at $5.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas EMBC's P/E ratio is 2.17. In terms of profitability, IGAP's ROE is +1.80%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, IGAP is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check EMBC's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
IGAP vs SMTI Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, SMTI has a market cap of 320.4M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while SMTI trades at $34.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas SMTI's P/E ratio is -580.83. In terms of profitability, IGAP's ROE is +1.80%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, IGAP is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
IGAP vs OSUR Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, OSUR has a market cap of 273M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas OSUR's P/E ratio is -5.75. In terms of profitability, IGAP's ROE is +1.80%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, IGAP is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check OSUR's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
IGAP vs NNNN Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NNNN has a market cap of 243.6M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while NNNN trades at $5.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NNNN's P/E ratio is 37.00. In terms of profitability, IGAP's ROE is +1.80%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, IGAP is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check NNNN's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
IGAP vs UTMD Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, UTMD has a market cap of 236M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while UTMD trades at $74.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas UTMD's P/E ratio is 21.93. In terms of profitability, IGAP's ROE is +1.80%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, IGAP is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
IGAP vs PDEX Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, PDEX has a market cap of 204.6M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while PDEX trades at $64.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas PDEX's P/E ratio is 15.51. In terms of profitability, IGAP's ROE is +1.80%, compared to PDEX's ROE of +0.31%. Regarding short-term risk, IGAP is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
IGAP vs KRMD Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, KRMD has a market cap of 136M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while KRMD trades at $2.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas KRMD's P/E ratio is -74.00. In terms of profitability, IGAP's ROE is +1.80%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, IGAP is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
IGAP vs STXS Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, STXS has a market cap of 115.6M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while STXS trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas STXS's P/E ratio is -6.94. In terms of profitability, IGAP's ROE is +1.80%, compared to STXS's ROE of -1.33%. Regarding short-term risk, IGAP is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check STXS's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
IGAP vs AKYA Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas AKYA's P/E ratio is -1.34. In terms of profitability, IGAP's ROE is +1.80%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, IGAP is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check AKYA's competition here
Daxor Corporation (NASDAQ: DXR)
IGAP vs DXR Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, DXR has a market cap of 61.9M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while DXR trades at $10.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas DXR's P/E ratio is 8.63. In terms of profitability, IGAP's ROE is +1.80%, compared to DXR's ROE of +0.13%. Regarding short-term risk, IGAP is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check DXR's competition here
SkyAI, Inc. (NASDAQ: STSS)
IGAP vs STSS Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas STSS's P/E ratio is -0.02. In terms of profitability, IGAP's ROE is +1.80%, compared to STSS's ROE of -1.54%. Regarding short-term risk, IGAP is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
IGAP vs OMIC Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas OMIC's P/E ratio is -0.58. In terms of profitability, IGAP's ROE is +1.80%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, IGAP is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check OMIC's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
IGAP vs POCI Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, POCI has a market cap of 48.8M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while POCI trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas POCI's P/E ratio is -9.70. In terms of profitability, IGAP's ROE is +1.80%, compared to POCI's ROE of -0.24%. Regarding short-term risk, IGAP is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check POCI's competition here
Nephros, Inc. (NASDAQ: NEPH)
IGAP vs NEPH Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NEPH has a market cap of 40.1M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while NEPH trades at $3.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NEPH's P/E ratio is 61.50. In terms of profitability, IGAP's ROE is +1.80%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, IGAP is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check NEPH's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
IGAP vs HBIO Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, HBIO has a market cap of 36.7M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while HBIO trades at $8.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas HBIO's P/E ratio is -22.58. In terms of profitability, IGAP's ROE is +1.80%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, IGAP is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check HBIO's competition here
Milestone Scientific Inc. (AMEX: MLSS)
IGAP vs MLSS Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, MLSS has a market cap of 33.5M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while MLSS trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas MLSS's P/E ratio is -7.57. In terms of profitability, IGAP's ROE is +1.80%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, IGAP is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check MLSS's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
IGAP vs SDC Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas SDC's P/E ratio is -0.03. In terms of profitability, IGAP's ROE is +1.80%, compared to SDC's ROE of -1.96%. Regarding short-term risk, IGAP is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
IGAP vs IVC Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas IVC's P/E ratio is -0.79. In terms of profitability, IGAP's ROE is +1.80%, compared to IVC's ROE of -0.46%. Regarding short-term risk, IGAP is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
IGAP vs RVP Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, RVP has a market cap of 21M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while RVP trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas RVP's P/E ratio is -5.83. In terms of profitability, IGAP's ROE is +1.80%, compared to RVP's ROE of -0.05%. Regarding short-term risk, IGAP is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
IGAP vs BNGO Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, BNGO has a market cap of 17.2M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while BNGO trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas BNGO's P/E ratio is -0.50. In terms of profitability, IGAP's ROE is +1.80%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, IGAP is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check BNGO's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
IGAP vs ZJYL Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ZJYL has a market cap of 15.6M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while ZJYL trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ZJYL's P/E ratio is 13.61. In terms of profitability, IGAP's ROE is +1.80%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, IGAP is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check ZJYL's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
IGAP vs RGNT Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, RGNT has a market cap of 12.7M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while RGNT trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas RGNT's P/E ratio is -0.07. In terms of profitability, IGAP's ROE is +1.80%, compared to RGNT's ROE of N/A. Regarding short-term risk, IGAP is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check RGNT's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
IGAP vs CUPR Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, CUPR has a market cap of 6.5M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while CUPR trades at $2.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas CUPR's P/E ratio is -1.75. In terms of profitability, IGAP's ROE is +1.80%, compared to CUPR's ROE of -15.69%. Regarding short-term risk, IGAP is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check CUPR's competition here
Femasys Inc. (NASDAQ: FEMY)
IGAP vs FEMY Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, FEMY has a market cap of 6.3M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while FEMY trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas FEMY's P/E ratio is -0.46. In terms of profitability, IGAP's ROE is +1.80%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, IGAP is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
IGAP vs LUCY Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, LUCY has a market cap of 5.6M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while LUCY trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas LUCY's P/E ratio is -0.69. In terms of profitability, IGAP's ROE is +1.80%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, IGAP is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
IGAP vs NSTG Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NSTG's P/E ratio is -0.03. In terms of profitability, IGAP's ROE is +1.80%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, IGAP is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
IGAP vs POAI Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas POAI's P/E ratio is -0.38. In terms of profitability, IGAP's ROE is +1.80%, compared to POAI's ROE of -21.19%. Regarding short-term risk, IGAP is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
IGAP vs MHUA Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas MHUA's P/E ratio is 0.25. In terms of profitability, IGAP's ROE is +1.80%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, IGAP is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
IGAP vs GMVD Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas GMVD's P/E ratio is -0.01. In terms of profitability, IGAP's ROE is +1.80%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, IGAP is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
IGAP vs GMVDW Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas GMVDW's P/E ratio is N/A. In terms of profitability, IGAP's ROE is +1.80%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, IGAP is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
IGAP vs AVGR Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas AVGR's P/E ratio is -0.05. In terms of profitability, IGAP's ROE is +1.80%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, IGAP is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
IGAP vs NXGL Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NXGL has a market cap of 1.5M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while NXGL trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NXGL's P/E ratio is -0.25. In terms of profitability, IGAP's ROE is +1.80%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, IGAP is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check NXGL's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
IGAP vs NXGLW Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NXGLW has a market cap of 1.1M. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, IGAP's ROE is +1.80%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, IGAP is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
IGAP vs LUCYW Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas LUCYW's P/E ratio is N/A. In terms of profitability, IGAP's ROE is +1.80%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, IGAP is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for IGAP.Check LUCYW's competition here
IntriCon Corporation (NASDAQ: IIN)
IGAP vs IIN Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, IIN has a market cap of 0. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas IIN's P/E ratio is 226.45. In terms of profitability, IGAP's ROE is +1.80%, compared to IIN's ROE of -0.00%. Regarding short-term risk, IGAP is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
IGAP vs ALOG Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ALOG's P/E ratio is 40.93. In terms of profitability, IGAP's ROE is +1.80%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, IGAP is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check ALOG's competition here
Invuity, Inc. (NASDAQ: IVTY)
IGAP vs IVTY Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas IVTY's P/E ratio is -3.80. In terms of profitability, IGAP's ROE is +1.80%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, IGAP is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check IVTY's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
IGAP vs HRC Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, HRC has a market cap of 0. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas HRC's P/E ratio is 41.92. In terms of profitability, IGAP's ROE is +1.80%, compared to HRC's ROE of +0.14%. Regarding short-term risk, IGAP is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check HRC's competition here
Apria, Inc. (NASDAQ: APR)
IGAP vs APR Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, APR has a market cap of 0. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas APR's P/E ratio is 22.59. In terms of profitability, IGAP's ROE is +1.80%, compared to APR's ROE of +9.81%. Regarding short-term risk, IGAP is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check APR's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
IGAP vs ATRS Comparison October 2026
GlucoTrack, Inc. (NASDAQ: IGAP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, IGAP is priced at $3.24 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ATRS's P/E ratio is 14.95. In terms of profitability, IGAP's ROE is +1.80%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, IGAP is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for IGAP.Check ATRS's competition here